Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Bay 11-7821Cat. No. 1744 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Alternative Name: Bay 11-7082 Chemical Name: (2E)-3-[(4-Methylphenyl)sulfonyl]-2-propenenitrile |
Biological Activity
Irreversible inhibitor of TNF-α-stimulated IκBα phosphorylation (IC50 ~ 10 μM); leads to decreased NF-κB and subsequent decreased expression of adhesion molecules. Also reversibly activates MAP kinases and stimulates apoptosis.Certificate of Analysis / Safety Data Sheet
References
Pierce et al (1997) Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J.Biol.Chem. 272 21096. PMID: 9261113.
Mori et al (2002) Bay 11-7082 inhibits transcription factor NF-κB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 100 1828. PMID: 12176906.
Scaife et al (2002) Nuclear factor κB inhibitors induce adhesion-dependent colon cancer apoptosis: implications for metastasis. Cancer Res. 62 6870. PMID: 12460901.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Bay 11-7821, supplier, Irreversible, inhibitors, TNF-α, TNF-alpha-induced, IκB, IκBα, IkappaBalpha, phosphorylation, IkappaB, Nuclear, Factor, Kappa, B, NF-κB, NF-kappaB, and, Cytokine, Signaling, Signalling, Transcription, Factors, Bay11-7821, Bay117082, NF-kB
Quick Order
Find multiple products by catalog number
Cancer Research Guide
Request your free copy
Highlights over 350 products for cancer research. Request a copy or view PDF today.
Immunology Guide
Highlights over 150 products for immunology research. Request a copy or view PDF today.
New Therapies and Challenges in Asthma
Written by Peter J. Barnes
'New Therapies, Challenges, and Breakthroughs in Asthma' highlights key pathways and new therapies used to treat asthma, including those currently in clinical development.
NF-κB Pathway
Signals through the NF-κB pathway are important in the inflammation and the adaptive and innate immune response. View pathway or download PDF today.
New Products in this Area
Selectively inhibits PKC-induced NF-κB activation
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.